The Board of Pharmacy has received notice of the following product recall:

Carton NOC	Lot Number	Expiration Date	Strength	Configuration/Count
0049-2340-45	AR5407	2022 FEB	40 mg	Carton containing 6 tablets (1 blister card x 6 tablets)
0049-2340-05	CD4565	2022 FEB	40 mg	Carton containing 12 tablets (2 blister cards x 6 tablets)

Pfizer Inc. is recalling the above referenced lots of RELPAX" (eletriptan HBr) tablets. Pfizer initiated this recall because these product lots may not meet Pfizer's in-house microbiological specification. Pfizer completed a Health Hazard Assessment, which concluded that the use of the Impacted product has an unlikely probability of being associated with adverse events such as a *decrease* in therapeutic efficacy or Infections in the general population. However, use of the impacted product in certain patient populations may be severe to life-threatening. The potential risk to a patient arising from this issue is considered to be low for the general population and high for lmmunocompromised patients. The recall of the above referenced lots of RELPAX0 (eletrlptan HBr) tablets is being conducted to the patient level.

The Board of Pharmacy strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.